Marcel J.M. Kofflard

Facilitators and barriers of research engagement in a large teaching hospital in the Netherlands: a narrative reflection

Céline de Goede, Marcel J.M. Kofflard, Lara Schram, Suzanne J. van den Toren

BACKGROUND: Healthcare organisations are facing major challenges, including workforce shortages, rising costs, and an aging population. Research engagement in hospitals plays a central role in addressing these challenges through quality improvement, innovation, and research aimed at more effective healthcare delivery. This study …

nl (code pays fourni par la source)

Mitochondrial Cardiomyopathy: Distinctive Cardiac Phenotype Detected with Cardiovascular MRI

Stephan A C Schoonvelde, Claudine W.B. Ruijmbeek, Judith M.A. Verhagen, Debby M.E.I. Hellebrekers et autres

Left ventricular hypertrophy (LVH) has a broad differential diagnosis. Pathogenic variants of mitochondrial DNA are a rare cause of LVH, and cardiac MRI is a powerful technique that may aid in differentiating such rare causes. This case report presents three siblings with …

nl (code pays fourni par la source)

Upper Extremity Function following Transradial Percutaneous Coronary Intervention: Results of the ARCUS Trial

Eva Zwaan, Elena S. Cheung, Alexander Ijsselmuiden, C.A.J. Holtzer et autres

Objectives. To determine the incidence of upper extremity dysfunction (UED), after a transradial percutaneous coronary intervention (TR-PCI). Background. Transradial approach (TRA) is the preferred approach for coronary interventions. However, upper extremity complications may be underreported. Methods. The ARCUS was designed as a …

nl (code pays fourni par la source)

Predictive Value of the (Quick)DASH Tool for Upper Extremity Dysfunction Following Percutaneous Coronary Intervention

Eva Zwaan, Elena S. Cheung, Alexander Ijsselmuiden, C.A.J. Holtzer et autres

Purpose: The use of the Disability of the Arm, Shoulder and Hand (DASH) questionnaire and its shortened version, the Quick DASH, have been used to assess upper extremity function following a transradial percutaneous coronary intervention (TR-PCI). However, the use of these scores …

nl (code pays fourni par la source)

The effect of trastuzumab on cardiac function in patients with HER2 ‐positive metastatic breast cancer and reduced baseline left ventricular ejection fraction

Nathalie I. Bouwer, Tessa G. Steenbruggen, Hánah N. Rier, Jos Kitzen et autres

We investigated the effect of trastuzumab on cardiac function in a real-world historic cohort of patients with HER2-positive metastatic breast cancer (MBC) with reduced baseline left ventricular ejection fraction (LVEF). Thirty-seven patients with HER2-positive MBC and baseline LVEF of 40% to 49% …

nl (code pays fourni par la source)

Treatment and Management of Upper Extremity Dysfunction Following Transradial Percutaneous Coronary Intervention: A Prospective Cohort Study

Elena S. Cheung, Eva Zwaan, Ton A.R. Schreuders, Marcel J.M. Kofflard et autres

BACKGROUND: The transradial artery access is the benchmark approach in transradial percutaneous coronary intervention (TR-PCI). The purpose of this study was to evaluate the different complications, treatments, and outcome of upper extremity dysfunction following a TR-PCI. METHODS: This was a prospective cohort …

nl (code pays fourni par la source)

2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab

Nathalie I. Bouwer, Crista Liesting, Marcel J.M. Kofflard, Jasper J. Brugts et autres

BACKGROUND: We aimed to study the predictive value of early two-dimensional echocardiography (2DE) speckle tracking (ST) for left ventricular ejection fraction (LVEF) changes during trastuzumab treatment for HER2-positive breast cancer. METHODS: HER2-positive breast cancer patients receiving trastuzumab, with or without anthracycline, underwent …

nl (code pays fourni par la source)

TCT-180 IMPROVE Hand Study—Similar Occurrence of Upper-Extremity Dysfunction Following Slender 5-F Versus 6-F Transradial Percutaneous Coronary Intervention

Elena Cheung, Marco Alings, C.A.J. Holtzer, Marcel J.M. Kofflard et autres

nl (code pays fourni par la source)

Usefulness of High-Sensitivity Cardiac Troponin T to Predict Long-Term Outcome in Patients with Hypertrophic Cardiomyopathy

D.H. Frank Gommans, G. Etienne Cramer, Michael A. Fouraux, Sanne Heijmans et autres

Since the first report of an association between cardiac troponin (cTn) and adverse outcome in hypertrophic cardiomyopathy (HD), there is a paucity in confirmative data. We performed a prospective, prespecified 5-year follow-up cohort study of 135 HC patients who participated in a …

nl, us, Gabon (code pays fourni par la source)

Brachial Artery Thrombosis as a Presentation of Non-Small Cell Pulmonary Carcinoma Growing Into the Left Atrium

Marie H E J van Wijngaarden, Marc C. J. M. Kock, Marcel J.M. Kofflard

We present a case of a thrombus in the left brachial artery as a cardioembolic presentation of pulmonary carcinoma. There have been few reports describing this clinical presentation, but if present, prognosis is very poor. Therefore, a cardioembolic event should be borne …

nl (code pays fourni par la source)

Abstract PS13-21: Cardiac function in patients receiving trastuzumab for HER2+ metastatic breast cancer with left ventricular ejection fraction<50% at baseline

Nathalie I. Bouwer, Tessa G. Steenbruggen, Hánah N. Rier, Jos Kitzen et autres

Abstract Research objectives and rationale Trastuzumab greatly enhances the efficacy of treatment in HER2+ metastatic breast cancer (MBC). Due to its potential to induce cardiomyopathy, however, trastuzumab is contraindicated in patients with baseline left ventricular ejection fraction (LVEF) <50%, although this criterion …

nl (code pays fourni par la source)

Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?

Nathalie I. Bouwer, Tessa G. Steenbruggen, Joost van Rosmalen, Hánah N. Rier et autres

PURPOSE: Patients with HER2-positive metastatic breast cancer (MBC) usually receive many years of trastuzumab treatment. It is unknown whether these patients require continuous left ventricular ejection fraction (LVEF) monitoring. We studied a real-world cohort to identify risk factors for cardiotoxicity to select …

nl (code pays fourni par la source)